Nephrotoxicity of FK 506 and cyclosporine when used as primary immunosuppression in liver transplant recipients.
Porayko
M K
MK
Mayo Clinic, Rochester, MN 55905.
Textor
S C
SC
Krom
R A
RA
Hay
J E
JE
Gores
G J
GJ
Wahlstrom
H E
HE
Sanchez-Urdazpal
L
L
Richards
T
T
Crotty
P
P
Beaver
S
S
D001379:Azathioprine / Q000627:therapeutic use; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000627:therapeutic use / Q000633:toxicity*; D004359:Drug Therapy, Combination; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007668:Kidney / Q000187:drug effects* / Q000473:pathology; D016031:Liver Transplantation / Q000276:immunology* / Q000502:physiology; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D016559:Tacrolimus / Q000627:therapeutic use / Q000633:toxicity*
D016572:Cyclosporine; D003404:Creatinine; D001379:Azathioprine; D011241:Prednisone; D016559:Tacrolimus